1357 related articles for article (PubMed ID: 33158436)
21. Reduction in cardiovascular disease events in patients with type 2 diabetes mellitus treated with a sodium-glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase-4 inhibitor: A real-world retrospective administrative database analysis in Japan.
Kashiwagi A; Shoji S; Onozawa S; Kosakai Y; Waratani M; Ito Y
J Diabetes Investig; 2022 Jul; 13(7):1175-1189. PubMed ID: 35243799
[TBL] [Abstract][Full Text] [Related]
22. Primary Occurrence of Cardiovascular Events After Adding Sodium-Glucose Cotransporter-2 Inhibitors or Glucagon-like Peptide-1 Receptor Agonists Compared With Dipeptidyl Peptidase-4 Inhibitors: A Cohort Study in Veterans With Diabetes.
Richardson TL; Halvorson AE; Hackstadt AJ; Hung AM; Greevy R; Grijalva CG; Elasy TA; Roumie CL
Ann Intern Med; 2023 Jun; 176(6):751-760. PubMed ID: 37155984
[TBL] [Abstract][Full Text] [Related]
23. Sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors on new-onset overall cancer in Type 2 diabetes mellitus: A population-based study.
Chung CT; Lakhani I; Chou OHI; Lee TTL; Dee EC; Ng K; Wong WT; Liu T; Lee S; Zhang Q; Cheung BMY; Tse G; Zhou J
Cancer Med; 2023 Jun; 12(11):12299-12315. PubMed ID: 37148547
[TBL] [Abstract][Full Text] [Related]
24. Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care.
Patorno E; Pawar A; Franklin JM; Najafzadeh M; Déruaz-Luyet A; Brodovicz KG; Sambevski S; Bessette LG; Santiago Ortiz AJ; Kulldorff M; Schneeweiss S
Circulation; 2019 Jun; 139(25):2822-2830. PubMed ID: 30955357
[TBL] [Abstract][Full Text] [Related]
25. Association of Sodium-Glucose Cotransporter 2 Inhibitor vs Dipeptidyl Peptidase-4 Inhibitor Use With Risk of Incident Obstructive Airway Disease and Exacerbation Events Among Patients With Type 2 Diabetes in Hong Kong.
Au PCM; Tan KCB; Lam DCL; Cheung BMY; Wong ICK; Kwok WC; Sing CW; Cheung CL
JAMA Netw Open; 2023 Jan; 6(1):e2251177. PubMed ID: 36648944
[TBL] [Abstract][Full Text] [Related]
26. Combination of sodium-glucose cotransporter 2 inhibitor and dipeptidyl peptidase-4 inhibitor in type 2 diabetes: a systematic review with meta-analysis.
Min SH; Yoon JH; Moon SJ; Hahn S; Cho YM
Sci Rep; 2018 Mar; 8(1):4466. PubMed ID: 29535389
[TBL] [Abstract][Full Text] [Related]
27. Cardiovascular, renal, and lower limb outcomes in patients with type 2 diabetes after percutaneous coronary intervention and treated with sodium-glucose cotransporter 2 inhibitors vs. dipeptidyl peptidase-4 inhibitors.
Lee HF; Chan YH; Chuang C; Li PR; Yeh YH; Hsiao FC; Peng JR; See LC
Eur Heart J Cardiovasc Pharmacother; 2023 Jun; 9(4):301-310. PubMed ID: 36639127
[TBL] [Abstract][Full Text] [Related]
28. A short-term follow-up of glycemic and body weight changes in diabetic patients who replaced dipeptidyl peptidase-4 inhibitors with the sodium-glucose cotransporter 2.
Huang CH; Huang YY; Hsu BR
Ann Saudi Med; 2018; 38(6):420-426. PubMed ID: 30531176
[TBL] [Abstract][Full Text] [Related]
29. Healthcare resource utilization and healthcare costs in patients with type 2 diabetes mellitus initiating sodium-glucose cotransporter 2 inhibitors vs dipeptidyl peptidase-4 inhibitors in Japan: A real-world administrative database analysis.
Kashiwagi A; Shoji S; Kosakai Y; Yoshinaga Y; Rokuda M
J Diabetes Investig; 2024 Mar; 15(3):374-387. PubMed ID: 38112598
[TBL] [Abstract][Full Text] [Related]
30. Clinical outcomes with the use of sodium-glucose cotransporter-2 inhibitors in patients with atrial fibrillation and type 2 diabetes mellitus: a multi-centre, real-world cohort study.
Jang J; Park S; Kim S; Kim SH; Oh YS; Sa YK; Hwang Y; Jang SW; Ihm SH; Choi Y
Eur J Prev Cardiol; 2024 Feb; 31(3):320-329. PubMed ID: 37798123
[TBL] [Abstract][Full Text] [Related]
31. Comparison of cardiovascular and renal outcomes between dapagliflozin and empagliflozin in patients with type 2 diabetes without prior cardiovascular or renal disease.
Lim J; Hwang IC; Choi HM; Yoon YE; Cho GY
PLoS One; 2022; 17(10):e0269414. PubMed ID: 36251654
[TBL] [Abstract][Full Text] [Related]
32. New-Onset Atrial Fibrillation in Patients With Type 2 Diabetes Treated With Novel Glucose-Lowering Therapies.
Hsiao FC; Yen KC; Chao TF; Chen SW; Chan YH; Chu PH
J Clin Endocrinol Metab; 2022 Aug; 107(9):2493-2499. PubMed ID: 35776065
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of combination therapy with SGLT2 and DPP4 inhibitors in the treatment of type 2 diabetes: A systematic review and meta-analysis.
Cho YK; Kang YM; Lee SE; Lee J; Park JY; Lee WJ; Kim YJ; Jung CH
Diabetes Metab; 2018 Nov; 44(5):393-401. PubMed ID: 29449146
[TBL] [Abstract][Full Text] [Related]
34. Impact of the initial decline in estimated glomerular filtration rate on the risk of new-onset atrial fibrillation and adverse cardiovascular and renal events in patients with type 2 diabetes treated with sodium-glucose co-transporter-2 inhibitors.
Chan YH; Chen SW; Chao TF; Kao YW; Huang CY; Chu PH
Diabetes Obes Metab; 2021 Sep; 23(9):2077-2089. PubMed ID: 34047459
[TBL] [Abstract][Full Text] [Related]
35. Sodium-Glucose Cotransporter-2 Inhibitor Prevents Stroke in Patients With Diabetes and Atrial Fibrillation.
Chang SN; Chen JJ; Huang PS; Wu CK; Wang YC; Hwang JJ; Tsai CT
J Am Heart Assoc; 2023 May; 12(10):e027764. PubMed ID: 37183872
[TBL] [Abstract][Full Text] [Related]
36. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
Ou HT; Chang KC; Li CY; Wu JS
Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
[TBL] [Abstract][Full Text] [Related]
37. Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, and Dipeptidyl Peptidase-4 Inhibitors, and Risk of Hospitalization.
Lyu B; Grams ME; Chang A; Inker LA; Coresh J; Shin JI
Am J Cardiol; 2022 Feb; 165():124-130. PubMed ID: 34937658
[TBL] [Abstract][Full Text] [Related]
38. Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction.
Gonzalez J; Bates BA; Setoguchi S; Gerhard T; Dave CV
Cardiovasc Diabetol; 2023 Mar; 22(1):54. PubMed ID: 36899387
[TBL] [Abstract][Full Text] [Related]
39. Sodium glucose cotransporter-2 inhibitor was associated with an improvement in left ventricular systolic function in patients with type 2 diabetes mellitus with impaired left ventricular systolic function.
Chan YH; Hsu TJ; Wang CL; Kao YW; Huang CY; Chu PH
ESC Heart Fail; 2020 Oct; 7(5):2784-2796. PubMed ID: 32627380
[TBL] [Abstract][Full Text] [Related]
40. Effects of sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors on diabetic retinopathy and its progression: A real-world Korean study.
Chung YR; Ha KH; Lee K; Kim DJ
PLoS One; 2019; 14(10):e0224549. PubMed ID: 31658289
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]